Skip to main content
Caplight Logo









Immugenia Inc.

Immugenia Inc.

Private
SherbrookeHealthcare & Life Scienceshttps://immugenia.com/

Last Round

Grant

Oct 15, 2024

Company Overview

Immugenia Inc. is a biotechnology company that develops immuno-oncology therapies by engineering hematopoietic stem cells to treat cancer and prevent relapses.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologyCAR-T therapychimeric antigen receptorhematopoietic stem cellHSCsynthetic promotergene therapycell therapycancer immunotherapynext-gen CARNK cell therapyin vivo gene deliverysolid tumor treatmentbiotech licensingdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Immugenia Inc. Comparables

Compare Immugenia Inc. with similar companies based on industry and business-model similarity.

Immugenia Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ensoma
76%
EXUMA Biotech
73%
Chromatin Bioscience
73%

Immugenia Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 15, 2024
Pre SeedOct 6, 2022

Key People

Founding team and executive leadership

Stéphane Gagné

Founder, President & CEO

Founding Team

Immugenia Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 15, 2024

    $3M grant received from Brain Canada Foundation and others.

  • Oct 6, 2022

    Secured funding from adMare BioInnovations, Accélérateur de création d'entreprises technologiques, and Sherbrooke Innopole.

Immugenia Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Immugenia Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Immugenia Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSherbrooke
Employee Range3
Year Founded2019
Last FundingOct 15, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?